Fallopian Tube Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Oct 2023 Pages: 169 SKU: IRTNTR73559

Fallopian Tube Cancer Treatment Market Forecast 2024-2028

The fallopian tube cancer treatment market size is projected to increase by USD 832.01 million at a CAGR of 10.35% between 2023 and 2028. The global awareness efforts led by CDC, Foundation for Women's Cancer, Target Ovarian Cancer, National Cervical Cancer Coalition, and American Cancer Society are key drivers propelling the growth of the global market. These initiatives, including awareness campaigns and events, promote early diagnosis and proactive management, elevating demand for therapeutics worldwide. This market analysis and report includes an in-depth analysis of the key market drivers, trends, and challenges during the forecasted period. 

Market Share

For More Highlights About this Report, Download Free Sample in a Minute 

Market Overview

This market focuses on therapies and drugs used to treat cancer of the fallopian tubes. This can sometimes spread to the ovaries, either directly through the tissue or fluids. The uterus (womb) is connected to the fallopian tubes at its upper ends. Typically, it doesn't directly involve the uterus in its early stages.  Surgical interventions, such as salpingo-oophorectomy, are commonly employed in the care treatment of this type of cancer.

Market Driver

Growing attention toward women's health is the key factor driving market growth.  The market encountered a challenge with the absence of understanding about various gynecologic cancer indications, such as fallopian tubes and ovarian cancer. The former, although originating primarily in the fallopian tubes, can have implications for adjacent reproductive organs like the ovaries and uterus due to their anatomical proximity. Thus, different organizations and governments across the globe are working on increasing awareness to overcome certain challenges associated with diagnosis and care treatment. The prevalence of this cancer underscores the need for continual advancements in diagnosis, treatment, and drug development. As the number of diagnosed cases rises, strategic collaborations and partnerships become pivotal in fostering innovative developments in therapies and diagnostic tools. 

Market Trends 

The advent of treatment vaccines for cancer is the primary trend shaping market growth. Vaccines are therapeutics that are issued to increase the body's immune response against a particular pathogen or a disease-causes gene. Carcinomas are among the most prevalent forms of cancer. For a long time, the global pharmaceuticals market only had preventive vaccines. However, the advances in the healthcare infrastructure have resulted in the advent of treatment vaccines, which have the ability to treat a certain indication after its progression

In addition, the drug and treatment vaccines that are currently being developed are made from cancer-specific antigens; however, research is also being conducted on the development of personalized treatment vaccines, in which the vaccine is produced from the patient tumor sample. Healthcare centers equipped with the necessary expertise in administering chemotherapy tailor treatments based on the phase of cancer and individual patient profiles, empowering informed decisions for optimal outcomes. Amidst stringent regulations, these centers operate while considering factors like discount programs offered by pharmaceutical companies.

Nowadays, multiple treatment vaccines are being developed in the late stages of clinical trials. Thus, such factors will drive the growth of the market during the forecast period.

Market Challenge

Difficulty in diagnosis is a challenge that affects market growth. Approximately 1,500 new cases of this type are diagnosed worldwide each year. Due to fallopian tube cancer's close relation to other gynecologic cancers, the diagnosis is favorably complex, as the signs are very similar to other indications. For instance, the complicated pathogenesis of the indication is also stopping the market from overcoming the challenge associated with the high mortality rate concerning its survival rate of the indication.

The survival rates vary based on several factors, including the stage at diagnosis, the extent of tumor spread, the type of trial received, and individual patient characteristics and immunotherapy.

Moreover, the market does not witness any research being conducted on new-age trial methods for the indication. However, chemotherapy limitations, including side effects and its inability to provide sustained relief, prompted pharmaceutical companies to explore alternative avenues. This exploration led to the development of novel targeted therapies designed to specifically inhibit certain overexpressed targets in cancerous cells and bolster the body's immunity against them through immunotherapy.

As a result, the difficulty in diagnosis of the indication is expected to pose a significant threat to the growth of the global market during the forecast period.

Market Segmentation

Diagnostic Methods through End-User Segment

The market share growth by the hospitals segment will be significant during the forecast period. The hospitals segment was valued at USD 565.70 million in 2018. Hospitals, the largest providers of cancer treatment, make up 66% of healthcare companies that are planning to change their entire business model. Hospital pharmacies constantly juggle cutting costs and staying within budget due to the high inbound costs of oncology medications. These factors are expected to augment the demand for these therapeutics through the hospital pharmacies segment, which will thus drive the growth of the hospitals segment of the global market during the forecast period

Get a glance at the market contribution of various segments Download the PDF Sample

Targeted Therapy and Immunotherapy through Product Segment 

The Ovarian cancer drug market is segmented as Targeted therapy drugs and chemotherapy. Targeted therapy drugs have the ability to suppress the activity of a specific cell, protein, or gene that is causing cancer. Targeted therapy options have shown a success rate of 80% in halting the progression of fallopian tube cancer. These drugs target the changes in cancer cells that are responsible for the cancer cells growth, division, and spreading. Targeted therapies can either be small molecule-based drugs or biologics, such as monoclonal antibodies. Small molecule-based drugs are highly effective in inhibiting cell growth by entering the cancer cells, and monoclonal antibody-based targeted therapies attach to a specific target that is found on a cancer cell, thereby inhibiting its ability to spread. Targeted therapies have the ability to mark the tumor cells, thereby triggering an immune response to kill the cell. They are also known to increase the immunity of the body against tumor cells while inhibiting their growth rate.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to forecast 39% of the growth of the global. The United States forecasts holds the largest share of the market, with a market penetration of over 45%. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

This market presents diverse trends across nations globally. High incidence regions such as the United States, Spain, Australia, Brazil, and India demonstrate varying approaches to combat this disease type, emphasizing early detection and enhanced treatment accessibility. Across Europe, including France, Italy, Denmark, Ireland, and Poland, notable strides in research and treatment methodologies have emerged. In the Asia-Pacific region, countries like Japan, Indonesia, Israel, Malaysia, and South Korea are witnessing advancements in both treatment options and awareness campaigns, while in Africa, nations like Saudi Arabia,  South Africa, Nigeria, Rwanda, and Uganda grapple with the need for improved healthcare infrastructure and awareness programs.

Key Companies in the Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market and forecast the growth rate of the industry.

Baxter International Inc.: The company offers fallopian tube cancer therapeutics such as DOXIL which is used for ovarian cancer treatment and Kaposi sarcoma.

Immunogen Inc- The company offers fallopian tube cancer therapeutics such as ZEJULA which is used as treatment for women with advanced ovarian cancer and provides ovarian cancer patients support after responding to platinum-based chemotherapy.

Johnson and Johnson -The company offers fallopian tube cancer therapeutics such as ZEJULA which is used as a treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

This market research and growth report forecasts detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Arrien Pharmaceuticals LLC
  • AstraZeneca Plc
  • BioVaxys Technology Corp.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Clinigen Group Plc
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • ImmunoGen Inc.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Ltd.
  • Clovis Oncology Inc.

Forecasts within the industry analysis emphasize the continued demand and advancements in chemotherapy agents, including checkpoint inhibitors and other targeted therapies, revolutionizing conventional treatment approaches. 

Market Analyst Overview

The Global Fallopian Tube Cancer Treatment Market is witnessing significant advancements in the management of this complex disease. With a focus on combating malignant cells like Papillary Serous Adenocarcinomas and Transitional Cell Carcinomas, treatment strategies include surgical interventions such as lymph node dissection, cytoreductive surgery, and hysterectomy. Additionally, advancements in technological innovations and product pipeline analysis are driving the development of targeted therapies for specific subtypes like Serous Adenocarcinomas and Endometrioid Adenocarcinomas. Moreover, the market is influenced by factors such as healthcare expenses, market regulations, and emerging markets, leading to strategic decisions like geographic expansions and product launches to tap into niche pockets of growth and capitalize on revenue pockets.

Fallopian Tube Cancer Therapeutics Market Scope

Report Coverage

Details

Page number

169

Base year

2023

Historic period

 2018 - 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.35%

Market growth 2024-2028

USD 832.01 million

Market structure

Fragmented

YoY growth 2023-2024(%)

8.01

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC, AstraZeneca Plc, Baxter International Inc., BioVaxys Technology Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Clinigen Group Plc, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ImmunoGen Inc., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Siemens Healthineers AG, Sun Pharmaceutical Industries Ltd., and Clovis Oncology Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in the Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market  size and its contribution of the market in focus to the parent market
  • Market growth analysis across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about companies
  • Market forecasting of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global fallopian tube cancer therapeutics market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global fallopian tube cancer therapeutics market 2018 - 2022 ($ million)
    • 4.2 End-user Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – End-user Segment 2018 - 2022 ($ million)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Hospitals - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
    • 6.4 Clinics and ASCs - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Clinics and ASCs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on Clinics and ASCs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on Clinics and ASCs - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Clinics and ASCs - Year-over-year growth 2023-2028 (%)
    • 6.5 Others - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by End-user
      • Exhibit 46: Market opportunity by End-user ($ million)
      • Exhibit 47: Data Table on Market opportunity by End-user ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 Targeted therapy - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Targeted therapy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Data Table on Targeted therapy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 54: Chart on Targeted therapy - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Targeted therapy - Year-over-year growth 2023-2028 (%)
    • 7.4 Chemotherapy - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by Product
      • Exhibit 60: Market opportunity by Product ($ million)
      • Exhibit 61: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 63: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 65: Chart on Geographic comparison
      • Exhibit 66: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 103: Market opportunity by geography ($ million)
      • Exhibit 104: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 107: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 108: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 109: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 110: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 111: AbbVie Inc. - Overview
              • Exhibit 112: AbbVie Inc. - Product / Service
              • Exhibit 113: AbbVie Inc. - Key news
              • Exhibit 114: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 115: Amgen Inc. - Overview
              • Exhibit 116: Amgen Inc. - Product / Service
              • Exhibit 117: Amgen Inc. - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 118: AstraZeneca Plc - Overview
              • Exhibit 119: AstraZeneca Plc - Product / Service
              • Exhibit 120: AstraZeneca Plc - Key news
              • Exhibit 121: AstraZeneca Plc - Key offerings
            • 12.6 Baxter International Inc.
              • Exhibit 122: Baxter International Inc. - Overview
              • Exhibit 123: Baxter International Inc. - Business segments
              • Exhibit 124: Baxter International Inc. - Key news
              • Exhibit 125: Baxter International Inc. - Key offerings
              • Exhibit 126: Baxter International Inc. - Segment focus
            • 12.7 Boehringer Ingelheim International GmbH
              • Exhibit 127: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 129: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 132: Bristol Myers Squibb Co. - Overview
              • Exhibit 133: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 134: Bristol Myers Squibb Co. - Key news
              • Exhibit 135: Bristol Myers Squibb Co. - Key offerings
            • 12.9 Clovis Oncology Inc.
              • Exhibit 136: Clovis Oncology Inc. - Overview
              • Exhibit 137: Clovis Oncology Inc. - Product / Service
              • Exhibit 138: Clovis Oncology Inc. - Key offerings
            • 12.10 Eli Lilly and Co.
              • Exhibit 139: Eli Lilly and Co. - Overview
              • Exhibit 140: Eli Lilly and Co. - Product / Service
              • Exhibit 141: Eli Lilly and Co. - Key news
              • Exhibit 142: Eli Lilly and Co. - Key offerings
            • 12.11 F. Hoffmann La Roche Ltd.
              • Exhibit 143: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 148: GlaxoSmithKline Plc - Overview
              • Exhibit 149: GlaxoSmithKline Plc - Business segments
              • Exhibit 150: GlaxoSmithKline Plc - Key news
              • Exhibit 151: GlaxoSmithKline Plc - Key offerings
              • Exhibit 152: GlaxoSmithKline Plc - Segment focus
            • 12.13 ImmunoGen Inc.
              • Exhibit 153: ImmunoGen Inc. - Overview
              • Exhibit 154: ImmunoGen Inc. - Product / Service
              • Exhibit 155: ImmunoGen Inc. - Key offerings
            • 12.14 Johnson and Johnson
              • Exhibit 156: Johnson and Johnson - Overview
              • Exhibit 157: Johnson and Johnson - Business segments
              • Exhibit 158: Johnson and Johnson - Key news
              • Exhibit 159: Johnson and Johnson - Key offerings
              • Exhibit 160: Johnson and Johnson - Segment focus
            • 12.15 Merck and Co. Inc.
              • Exhibit 161: Merck and Co. Inc. - Overview
              • Exhibit 162: Merck and Co. Inc. - Business segments
              • Exhibit 163: Merck and Co. Inc. - Key news
              • Exhibit 164: Merck and Co. Inc. - Key offerings
              • Exhibit 165: Merck and Co. Inc. - Segment focus
            • 12.16 Novartis AG
              • Exhibit 166: Novartis AG - Overview
              • Exhibit 167: Novartis AG - Business segments
              • Exhibit 168: Novartis AG - Key offerings
              • Exhibit 169: Novartis AG - Segment focus
            • 12.17 Pfizer Inc.
              • Exhibit 170: Pfizer Inc. - Overview
              • Exhibit 171: Pfizer Inc. - Product / Service
              • Exhibit 172: Pfizer Inc. - Key news
              • Exhibit 173: Pfizer Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 174: Inclusions checklist
                • Exhibit 175: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 176: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 177: Research methodology
                • Exhibit 178: Validation techniques employed for market sizing
                • Exhibit 179: Information sources
              • 13.5 List of abbreviations
                • Exhibit 180: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              fallopian tube cancer therapeutics market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis